Literature DB >> 29360199

Trimodal system for in vivo skin cancer screening with combined optical coherence tomography-Raman and colocalized optoacoustic measurements.

Arthur Varkentin1, Mikhail Mazurenka1, Elias Blumenröther1, Lea Behrendt1, Steffen Emmert2, Uwe Morgner3, Merve Meinhardt-Wollweber1, Maik Rahlves1, Bernhard Roth1.   

Abstract

A new multimodal system for rapid, noninvasive in vivo skin cancer screening is presented, combining optical coherence tomography (OCT) and optoacoustic (OA) modalities to provide precise tumor depth determination with a Raman spectroscopic modality capable of detecting the lesion type and, thus, providing diagnostic capability. Both OA and Raman setups use wide field skin illumination to ensure the compliance with maximum permissible exposure (MPE) requirements. The Raman signal is collected via the OCT scanning lens to maximize the signal-to-noise ratio of the measured signal while keeping radiation levels below MPE limits. OCT is used to optically determine the tumor thickness and for volumetric imaging whereas OA utilizes acoustic signals generated by optical absorption contrast for thickness determination at potentially higher penetration depths compared to OCT. Preliminary results of first clinical trials using our setup are presented. The measured lesion depth is in good agreement with histology results, while Raman measurements show distinctive differences between normal skin and melanocytic lesions, and, moreover, between different skin areas. In future, we will validate the setup presented for reliable detection of pathophysiological parameters, morphology and thickness of suspicious skin lesions.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Raman spectroscopy; multimodal; optical coherence tomography; optoacoustics; skin cancer

Mesh:

Year:  2018        PMID: 29360199     DOI: 10.1002/jbio.201700288

Source DB:  PubMed          Journal:  J Biophotonics        ISSN: 1864-063X            Impact factor:   3.207


  6 in total

1.  Optical coherence tomography-guided confocal Raman microspectroscopy for rapid measurements in tissues.

Authors:  Xiaojing Ren; Kan Lin; Chao-Mao Hsieh; Linbo Liu; Xin Ge; Quan Liu
Journal:  Biomed Opt Express       Date:  2021-12-14       Impact factor: 3.732

2.  Co-localized line-field confocal optical coherence tomography and confocal Raman microspectroscopy for three-dimensional high-resolution morphological and molecular characterization of skin tissues ex vivo.

Authors:  Léna Waszczuk; Jonas Ogien; Jean-Luc Perrot; Arnaud Dubois
Journal:  Biomed Opt Express       Date:  2022-03-25       Impact factor: 3.562

3.  Morpho-molecular signal correlation between optical coherence tomography and Raman spectroscopy for superior image interpretation and clinical diagnosis.

Authors:  Iwan W Schie; Fabian Placzek; Florian Knorr; Eliana Cordero; Lara M Wurster; Gregers G Hermann; Karin Mogensen; Thomas Hasselager; Wolfgang Drexler; Jürgen Popp; Rainer A Leitgeb
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 4.  Looking for a perfect match: multimodal combinations of Raman spectroscopy for biomedical applications.

Authors:  Iwan Schie; Clara Stiebing; Jürgen Popp
Journal:  J Biomed Opt       Date:  2021-08       Impact factor: 3.170

Review 5.  Skin cancer detection using non-invasive techniques.

Authors:  Vigneswaran Narayanamurthy; P Padmapriya; A Noorasafrin; B Pooja; K Hema; Al'aina Yuhainis Firus Khan; K Nithyakalyani; Fahmi Samsuri
Journal:  RSC Adv       Date:  2018-08-06       Impact factor: 4.036

6.  Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features.

Authors:  David Orlando Grajales Lopera; Fabien Picot; Roozbeh Shams; Frédérick Dallaire; Guillaume Sheehy; Stephanie Alley; Maroie Barkati; Guila Delouya; Jean-Francois Carrier; Mirela Birlea; Dominique Trudel; Frédéric Leblond; Cynthia Ménard; Samuel Kadoury
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.